Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Tancevski, I; Wehinger, A; Demetz, E; Hoefer, J; Eller, P; Huber, E; Stanzl, U; Duwensee, K; Auer, K; Schgoer, W; Kuhn, V; Fievet, C; Stellaard, F; Rudling, M; Foeger, B; Patsch, JR; Ritsch, A.
The thyromimetic T-0681 protects from atherosclerosis.
J Lipid Res. 2009; 50(5):938-944
Doi: 10.1194/jlr.M800553-JLR200
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Eller Philipp
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a >70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.
- Find related publications in this database (using NLM MeSH Indexing)
-
Animals -
-
Anticholesteremic Agents - therapeutic use
-
Antigens, CD36 - metabolism
-
Aorta - anatomy and histology Aorta - pathology
-
Atherosclerosis - prevention and control
-
Cell Line -
-
Cholesterol, Dietary -
-
Diet -
-
Disease Models, Animal -
-
Humans -
-
Hyperlipidemias - drug therapy
-
Lipid Metabolism -
-
Liver - metabolism
-
Male -
-
Malonates - therapeutic use
-
Phenyl Ethers - therapeutic use
-
Rabbits -
- Find related publications in this database (Keywords)
-
liver-selective thyromimetic
-
low density lipoprotein receptor
-
scavenger receptor class B, type I
-
potential side effects